2216-93-5

Basic information

• Product Name: 2,4-Imidazolidinedione, 5-ethyl-5-phenyl-, (+-)-
• Synonyms: Nsc 33388
• CAS NO: 2216-93-5
• Molecular Formula: C₁₁H₁₂N₂O₂
• Molecular Weight: 0
• Mol File: 2216-93-5.mol
• Article Data: 9

Chemical Properties

• Boiling Point: °Cat760mmHg
• Flash Point: °C
• Appearance: /
• Density: 1.173g/cm³
• CAS DataBase Reference: 2,4-Imidazolidinedione, 5-ethyl-5-phenyl-, (+-)-(CAS DataBase Reference)
• NIST Chemistry Reference: 2,4-Imidazolidinedione, 5-ethyl-5-phenyl-, (+-)-(2216-93-5)
• EPA Substance Registry System: 2,4-Imidazolidinedione, 5-ethyl-5-phenyl-, (+-)-(2216-93-5)

Safety Data

• Hazardous Substances Data: 2216-93-5(Hazardous Substances Data)

Usage

General Description

2,4-Imidazolidinedione, 5-ethyl-5-phenyl-, (+-)-, also known as phenytoin, is a common anti-seizure medication used to treat epilepsy and certain types of seizures. It works by stabilizing electrical activity in the brain. Phenytion is an anticonvulsant that is part of the hydantoin family and is often used in combination with other medications to control seizures. It is available in various forms including tablets, capsules, and suspension, and is usually taken by mouth. Common side effects of phenytoin include dizziness, drowsiness, and nausea. Long-term use of phenytoin has been associated with potential side effects such as osteoporosis and an increased risk of gum disease.

Upstream product

• 74-90-8 hydrogen cyanide 
• 124-38-9 carbon dioxide 
• 93-55-0 1-phenyl-propan-1-one 
• 298689-33-5 2-amino-2-phenylbutyronitrile 
• 33875-36-4 2-Isocyanato-2-phenyl-butyronitrile 
• 75356-44-4 (1-Cyano-1-phenyl-propyl)-urea 
• 506-87-6 ammonium carbonate 
• 75356-38-6 racem-α-Aethyl-α-cyan-benzylisocyanat 
• 75-44-5 phosgene 
• 102-09-0 bis(phenyl) carbonate 
• 5438-07-3 2-amino-2-phenylbutanoic acid 
• 57-13-6 urea 
• 75356-44-4 (1-cyano-1-phenyl-propyl)-urea 
• 80544-75-8 (rac)-2-Cyan-2-phenylbutanamid 

Downstream Products

• 968-51-4 5-ethyl-3-morpholin-4-ylmethyl-5-phenyl-imidazolidine-2,4-dione 
• 771515-54-9 C₁₉H₂₀N₂O₂ 
• 857037-18-4 C₁₈H₁₇ClN₂O₂ 
• 849190-27-8 C₁₈H₁₇BrN₂O₂ 
• 778619-05-9 4-[(4-ethyl-2,5-dioxo-4-phenyl-1-imidazolidinyl)methyl]-benzonitrile 
• 790676-34-5 5-ethyl-3-(4-methoxybenzyl)-5-phenyl-2,4-imidazolidinedione 
• 50-12-4 mephenytoin 
• 21435-70-1 5-ethyl-5-phenyl-3-(toluene-4-sulfonyl)-imidazolidine-2,4-dione 
• 5062-78-2 4-Ethyl-4-phenylimidazolidin-2-on 
• 65567-32-0 (-)-Nirvanol 
• 65567-34-2 (+)-Nirvanol 
• 5417-76-5 5-ethyl-5-phenyl-imidazolidine-2,4-dithione 
• 99533-93-4 5-ethyl-5-phenyl-3-propyl-imidazolidine-2,4-dione 
• 93879-40-4 (+/-)-N-3-benzyl-Nirvanol 

Relevant articles and documents

Continuous Synthesis of Hydantoins: Intensifying the Bucherer-Bergs Reaction

A continuous Bucherer-Bergs hydantoin synthesis utilizing intensified conditions is reported. The methodology is characterized by a two-feed flow approach to independently feed the organic substrate and the aqueous reagent solution. The increased interfacial area of the biphasic reaction mixture and the lack of headspace enabled almost quantitative conversions within ca. 30 minutes at 120 °C and 20 bar even for unpolar starting materials. In addition, a selective N(3)-monoalkylation of the resulting heterocycles under batch microwave conditions is reported yielding potential acetylcholinesterase inhibitors.

New derivatives of hydantoin as potential antiproliferative agents: Biological and structural characterization in combination with quantum chemical calculations

Two new series of hydantoin derivatives, 3-(4-substituted benzyl)-5,5-diphenyl- and 3-(4-substituted benzyl)-5-ethyl-5-phenylhydantoins, were synthesized and their antiproliferative activity was tested against human colon cancer HCT-116 and breast cancer

Synthesis, structural and biological characterization of 5-phenylhydantoin derivatives as potential anticonvulsant agents

Considering the importance of hydantoin derivatives in treatment of status epilepticus, four 5-phenylhydantoins, whose lipophilicities were estimated to be similar to that of phenytoin, were synthesized. Evaluation of their anticonvulsant activities was performed on rats by subcutaneous pentylenetetrazol seizure test and intravenous pentylenetetrazol threshold test, and spontaneous locomotor activity test was used to assess possible sedative effects. X-ray analysis of three compounds suggested that certain analogies might be drawn between interactions in crystal packing and biological interactions responsible for their anticonvulsant activity. It was found that 5-ethyl-5-phenyl- 3-propylhydantoin exhibits the most favorable pharmacological properties among the synthesized compounds, i.e., anticonvulsant activity comparable to phenytoin with lower liability for induction of sedation in rats.